Investigation of High-Mobility Group Box 1 Protein Levels in Gastrointestinal Malignities
Hanım Seval Savaş1, Hülya Çiçek2*, Mustafa Yildirım3 and Hüseyin Gürbüz4
1Specialist Dietitian, Department of Medical Biochemistry, Gaziantep University Institute of Health Sciences, Gaziantep, Turkey
2Professor, Department of Medical Biochemistry, Gaziantep University School of Medicine, Gaziantep, Turkey
3Professor, Faculty of Medicine, Department of Internal Medicine and Medical Oncology, SANKO University, Gaziantep, Turkey
4Gaziantep Dr. Ersin Arslan Training and Research Hospital, Department of Emergency Medicine, Gaziantep, Turkey
*Corresponding Author: Hülya Çiçek, Professor, Department of Medical Biochemistry, Gaziantep University School of Medicine, Gaziantep, Turkey.
March 07, 2022; Published: May 10, 2022
Cancer is a serious health problem that is common in humans and its development is quite complex. Protein-coding genes, tumor suppressor genes, and some biomarkers responsible for the growth, differentiation, and metastasis of cancer cells are used in the diagnosis and treatment of cancer patients. Gastrointestinal cancers are the most common cancers worldwide and cause more deaths than any other type of cancer. The poor prognosis of patients diagnosed with gastrointestinal cancer has made primary prevention a potentially attractive approach. Despite improved diagnosis and treatment methods, survival rates are low. Therefore, early diagnosis and treatment of cancer are important. High Mobility Group Box 1 (HMGB1), an important biomarker in cancers, regulates DNA and transcription. HMGB1 plays a role in cancer progression, angiogenesis, and metastasis development.
Plasma samples were used in this case-control study involving 68 gastrointestinal cancer patients and 40 healthy controls. HMGB1 was measured by the ELISA method.
There was a significant relationship between the patient and control groups in terms of HMGB1 level. It was determined that 98.5% sensitivity, 90% specificity, and 19.31 values could distinguish the patient and control groups. There is no significant difference in HMGB1 levels among gastrointestinal malignancy groups. We found evidence of a significant association between HMGB1 protein and all gastrointestinal cancers. Since results suggest that HMGB1 may play an important role in cancer diagnosis, studies on this marker should be increased.
HMGB1 may be a new serological biomarker for its contribution to early diagnosis and treatment in cancers with poor prognosis and high mortality, such as the digestive system.
Keywords: HMGB1; Gastrointestinal Cancer; Cancer Diagnosis
- Bianchi ME and Beltrame M. “Upwardly mobile proteins”. EMBO Reports 2 (2000): 109-114.
- Ronfani L., et al. “Reduced fertility and spermatogenesis defects in mice lacking chromosomal protein Hmgb2”. Development 8 (2001): 1265-1273.
- Janko C., et al. “Redox modulation of HMGB1-related signaling”. Antioxidants and Redox Signaling7 (2014): 1075-1085.
- Agresti A and Bianchi ME. “HMGB proteins and gene expression”. Current Opinion in Genetics and Development 2 (2003): 170-178.
- Yıldırım M., et al. “High Mobility Group Box 1 and Cancer”. Acıbadem University Journal of Health Sciences 3:182-186.
- Tang D., et al. “High-mobility group box 1 and cancer”. Biochimica et Biophysica Acta (BBA)-Gene Regulatory Mechanisms1-2 (2010): 131-140.
- Palumbo R., et al. “Cells migrating to sites of tissue damage in response to the danger signal HMGB1 require NF-κB activation”. The Journal of Cell Biology1 (2001): 33-40.
- Park JS., et al. “High mobility group box 1 protein interacts with multiple Toll-like receptors”. American Journal of Physiology-Cell Physiology 3 (2006): C917-C24.
- Scaffidi P., et al. “Release of chromatin protein HMGB1 by necrotic cells triggers inflammation”. Nature6894 (2002): 191-195.
- Kang R., et al. “HMGB1 in cancer: good, bad, or both?” Clinical Cancer Research15 (2013): 4046-4057.
- Maeda S., et al. “Essential roles of high-mobility group box 1 in the development of murine colitis and colitis-associated cancer”. Biochemical and Biophysical Research Communications2 (2007)394-400.
- Wu T., et al. “HMGB1 overexpression as a prognostic factor for survival in cancer: a meta-analysis and systematic review”. Oncotarget31 (2006): 50417.
- Kang R., et al. “Intracellular HMGB1 as a novel tumor suppressor of pancreatic cancer”. Cell Research7 (2017): 916-932.
- Zhang QY., et al. “Autophagy-mediated HMGB1 release promotes gastric cancer cell survival via RAGE activation of extracellular signal-regulated kinases ½”. Oncology Reports4 (2015): 1630-1638.
- Huang M., et al. “Translationally controlled tumor protein affects colorectal cancer metastasis through the high mobility group box 1-dependent pathway”. International Journal of Oncology4 (2018): 1481-1492.
- Chen R., et al. “High mobility group protein B1 controls liver cancer initiation through yes-associated protein -dependent aerobic glycolysis”. Hepatology (Baltimore, Md) 67.5 (2018): 1823-1841.
- Satoh M., et al. “High mobility group box 1 can be used to monitor perioperative course in patients with liver cancer”. Surgical Oncology 33 (2020): 216-221.
- Yıldırım M., et al. “High Mobility Group Box 1 and Cancer” (2014).
- Wang X., et al. “The role of HMGB1 signaling pathway in the development and progression of hepatocellular carcinoma: a review”. International Journal of Molecular Sciences9 (2015): 22527-22540.
- Ohmori H., et al. “Non-histone nuclear factor HMGB1 as a therapeutic target in colorectal cancer”. Expert Opinion on Therapeutic Targets2 (2011): 183-193.
- Fang J., et al. “Bioinformatics analysis of the prognosis and biological significance of HMGB1, HMGB2, and HMGB3 in gastric cancer”. Journal of Cellular Physiology4 (2020): 3438-3446.
- Kang HJ., et al. “Non-histone nuclear factor HMGB1 is phosphorylated and secreted in colon cancers”. Laboratory Investigation8 (2009): 948-959.
- Lee H., et al. “Diagnostic significance of serum HMGB1 in colorectal carcinomas”. PloS One4 (2012): e34318.
- Dong YD., et al. “Expression and clinical significance of HMGB1 in human liver cancer: Knockdown inhibitors tumor growth and metastasis in vitro and in vivo”. Oncology Reports 1 (2013): 87-94.
- Chung HW., et al. “Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer”. Journal of Translational Medicine1 (2009): 1-11.
- Yılmaz N., et al. “The role of HMGB1 in gastrointestinal cancers”. Archives of Medical Science-Civilization Diseases1 (2021): 1-7.
- Klune JR., et al. “HMGB1: endogenous danger signaling”. Molecular Medicine7 (2008): 476-484.